Unveiling the Future of Cellular Renewal
Hemifusomex™: Pioneering Cellular Continuity
Discover Hemifusomex™, a groundbreaking innovation in cellular science, designed to enhance membrane dynamics and promote cellular integrity.
Understanding Hemifusomex™
The Science Behind Hemifusomex™
Peptourbillon™ Architecture
The Peptourbillon™ architecture is a sophisticated multilayer peptide system that enhances membrane stability and facilitates cellular communication.
Membrane Modulation
Our technology modulates the membrane of renewal, promoting efficient cellular processes and reducing cellular stress.
Enhanced Cellular Function
Hemifusomex™ supports enhanced cellular function by optimizing receptor recycling and reducing ubiquitin aggregates.
How the hemifusome record developed
Hemifusomes entered the literature in 2024 and were peer-reviewed in 2025. Four dated, checkable records — every one linked.
Aug 2024
bioRxiv preprint
Tavakoli, Hu, Ebrahim and Kachar post “Hemifusomes and Interacting Proteolipid Nanodroplets: Formation of a Novel Cellular Organelle Complex” on bioRxiv, 29 August 2024. Preprint
Oct 2024
Research Square preprint
A revised version appears on Research Square, 21 October 2024, under the title the journal paper would carry. PubMed 39502775
May 2025
Nature Communications
Peer review lands the work in Nature Communications on 17 May 2025 — the first reviewed description of the organelle. Article
Sep 2026
Cell Communication and Signaling
A review on 9 September 2026 synthesises the model and its open questions. That is the corpus to date. Review
Where this stands
What is established. Hemifusomes are heterotypic vesicle pairs joined by an extended hemifusion diaphragm, described from in-situ cryo-electron tomography by researchers at the NIH and the University of Virginia School of Medicine. Nature Communications, 2025
What is not established. Any effect of Hemifusomex™ on that machinery. Panacea Bio Chem has published nothing on it, and this site carries no figure, trial or outcome for it.
Bogdan Dicoias
Lead Bioscientist, Panacea Bio Chem Ltd
What the programme is. HMX-101 (Hemifusin-A), a 23-residue amphipathic helix, formulated in the Peptourbillon™ layered architecture under TgShift™ control. Exploratory, in development, led by Bogdan Dicoias.
Bogdan Dicoias
Lead Bioscientist, Panacea Bio Chem Ltd
Dive Deeper into Hemifusomex™
Uncover the science behind Hemifusomex™ and explore how it is reshaping the landscape of cellular technology. Click below to learn more about our innovative approach.